Market closedNon-fractional
Royalty Pharma/RPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Royalty Pharma
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Ticker
RPRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
New York, United States
Employees
-
Website
www.royaltypharma.com
Royalty Pharma Metrics
BasicAdvanced
$13B
Market cap
14.65
P/E ratio
$1.96
EPS
0.47
Beta
$0.81
Dividend rate
2.82%
Dividend yield
Price and volume
Market cap
$13B
Beta
0.47
Dividend rate
$0.81
Financial strength
Current ratio
12.52
Quick ratio
12.48
Long term debt to equity
62.242
Total debt to equity
62.242
Dividend payout ratio (TTM)
45.50%
Interest coverage (TTM)
5.10%
Management effectiveness
Return on assets (TTM)
3.54%
Return on equity (TTM)
12.06%
Valuation
Price to earnings (TTM)
14.652
Price to revenue (TTM)
5.227
Price to book
1.99
Price to tangible book (TTM)
1.99
Price to free cash flow (TTM)
11.485
Dividend yield (TTM)
2.82%
Growth
Revenue change (TTM)
-5.11%
Earnings per share change (TTM)
136.73%
3-year revenue growth (CAGR)
0.66%
3-year earnings per share growth (CAGR)
13.69%
3-year dividend per share growth (CAGR)
19.89%
What the Analysts think about Royalty Pharma
Analyst Ratings
Majority rating from 8 analysts.
Royalty Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$568M
-4.71%
Net income
$4.7M
-99.05%
Profit margin
0.82%
-99.01%
Royalty Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.84
$0.79
$1.15
$0.98
-
Expected
$0.81
$0.76
$1.01
$0.98
$0.97
Surprise
3.96%
4.50%
13.86%
-0.20%
-
Royalty Pharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
Aug
16
Royalty Pharma
Dividend·Ex-dividend
Sept
13
Royalty Pharma
Dividend·Payment
$0.21
Per share
FAQs
What’s the current market cap for Royalty Pharma stock?
Royalty Pharma (RPRX) has a market cap of $13B as of July 27, 2024.
What is the P/E ratio for Royalty Pharma stock?
The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 14.65 as of July 27, 2024.
Does Royalty Pharma stock pay dividends?
Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of July 27, 2024, the dividend rate is $0.81 and the yield is 2.82%. Royalty Pharma has a payout ratio of 45.5% on a trailing twelve-month basis.
When is the next Royalty Pharma dividend payment date?
The next Royalty Pharma (RPRX) dividend payment is scheduled for September 13, 2024.
What is the beta indicator for Royalty Pharma?
Royalty Pharma (RPRX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Royalty Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.